TY - JOUR T1 - Influence of sex on disease severity in children with COVID-19 and Multisystem Inflammatory Syndrome in Latin America JF - medRxiv DO - 10.1101/2021.02.07.21251212 SP - 2021.02.07.21251212 AU - Martin Brizuela AU - Jacopo Lenzi AU - Rolando Ulloa-Gutiérrez AU - Antúnez-Montes Omar Yassef AU - Jorge Alberto Rios Aida AU - Olguita del Aguila AU - Erick Arteaga-Menchaca AU - Francisco Campos AU - Fadia Uribe AU - Andrea Parra Buitrago AU - Lina Maria Betancur Londoño AU - Jessica Gómez-Vargas AU - Adriana Yock-Corrales AU - Danilo Buonsenso Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/09/2021.02.07.21251212.abstract N2 - Data from adult studies how that COVID-19 is more severe in men than women. However, no data are available for the pediatric population. For this reason, we performed this study aiming to understand if sex influenced disease severity and outcomes in a large cohort of latin-american children with COVID-19 and Multisystem Inflammatory Syndrome (MIS-C). We found that a higher percentage of male children developed MIS-C (8.9% vs 5% in females) and died (1.2% and 0.4% in females), although on multivariate adjusted analyses the only statistically significant difference was found in need of hospitalization, with females less frequently admitted compared with boys (25.6% vs 35.4%). This data are preliminary and need further independent studies to better assess the role of sex.Competing Interest StatementThe authors have declared no competing interest.Funding Statementnothing to declareAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed and approved by the CoviD in south american children study Group core group and approved by the Ethics Committee of the coordinating center and by each participating center (Mexico: COMINVETICA30072020CEI0100120160207; Colombia: PECEIFT06; Peru: No. 42IETSIESSALUD2020; Costa Rica: CECHNN2432020). The study was conducted in accordance with the Declaration of Helsinki and its amendments. No personal or identifiable data were collected during the conduct of this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesavailable upon request to the corresponding author ER -